Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
Hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk. Asian subjects are metabolically more susceptible to hypertriglyceridemia than other ethnicities. Fenofibrate...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Diabetes Association
2024-03-01
|
| Series: | Diabetes & Metabolism Journal |
| Subjects: | |
| Online Access: | http://e-dmj.org/upload/pdf/dmj-2023-0168.pdf |
| _version_ | 1797221630173249536 |
|---|---|
| author | Chaicharn Deerochanawong Sin Gon Kim Yu-Cheng Chang |
| author_facet | Chaicharn Deerochanawong Sin Gon Kim Yu-Cheng Chang |
| author_sort | Chaicharn Deerochanawong |
| collection | DOAJ |
| description | Hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk. Asian subjects are metabolically more susceptible to hypertriglyceridemia than other ethnicities. Fenofibrate regulates hypertriglyceridemia, raises HDL-C levels, and is a recommended treatment for dyslipidemia. However, data on fenofibrate use across different Asian regions are limited. This narrative review summarizes the efficacy and safety data of fenofibrate in Asian subjects with dyslipidemia and related comorbidities (diabetes, metabolic syndrome, diabetic retinopathy, and diabetic nephropathy). Long-term fenofibrate use resulted in fewer cardiovascular (CV) events and reduced the composite of heart failure hospitalizations or CV mortality in type 2 diabetes mellitus. Fenofibrate plays a significant role in improving irisin resistance and microalbuminuria, inhibiting inflammatory responses, and reducing retinopathy incidence. Fenofibrate plus statin combination significantly reduced composite CV events risk in patients with metabolic syndrome and demonstrated decreased triglyceride and increased HDL-C levels with an acceptable safety profile in those with high CV or ASCVD risk. Nevertheless, care is necessary with fenofibrate use due to possible hepatic and renal toxicities in vulnerable individuals. Long-term trials and real-world studies are needed to confirm the clinical benefits of fenofibrate in the heterogeneous Asian population with dyslipidemia. |
| first_indexed | 2024-04-24T13:08:29Z |
| format | Article |
| id | doaj.art-71a78d56ef4a4f1daec7e774e160ab4b |
| institution | Directory Open Access Journal |
| issn | 2233-6079 2233-6087 |
| language | English |
| last_indexed | 2024-04-24T13:08:29Z |
| publishDate | 2024-03-01 |
| publisher | Korean Diabetes Association |
| record_format | Article |
| series | Diabetes & Metabolism Journal |
| spelling | doaj.art-71a78d56ef4a4f1daec7e774e160ab4b2024-04-05T06:03:30ZengKorean Diabetes AssociationDiabetes & Metabolism Journal2233-60792233-60872024-03-0148218419510.4093/dmj.2023.01682800Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative ReviewChaicharn Deerochanawong0Sin Gon Kim1Yu-Cheng Chang2 Diabetes and Endocrinology Unit, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea Department of Bioinformatics and Medical Engineering, Asia University, Taichung, TaiwanHypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk. Asian subjects are metabolically more susceptible to hypertriglyceridemia than other ethnicities. Fenofibrate regulates hypertriglyceridemia, raises HDL-C levels, and is a recommended treatment for dyslipidemia. However, data on fenofibrate use across different Asian regions are limited. This narrative review summarizes the efficacy and safety data of fenofibrate in Asian subjects with dyslipidemia and related comorbidities (diabetes, metabolic syndrome, diabetic retinopathy, and diabetic nephropathy). Long-term fenofibrate use resulted in fewer cardiovascular (CV) events and reduced the composite of heart failure hospitalizations or CV mortality in type 2 diabetes mellitus. Fenofibrate plays a significant role in improving irisin resistance and microalbuminuria, inhibiting inflammatory responses, and reducing retinopathy incidence. Fenofibrate plus statin combination significantly reduced composite CV events risk in patients with metabolic syndrome and demonstrated decreased triglyceride and increased HDL-C levels with an acceptable safety profile in those with high CV or ASCVD risk. Nevertheless, care is necessary with fenofibrate use due to possible hepatic and renal toxicities in vulnerable individuals. Long-term trials and real-world studies are needed to confirm the clinical benefits of fenofibrate in the heterogeneous Asian population with dyslipidemia.http://e-dmj.org/upload/pdf/dmj-2023-0168.pdfasian peoplediabetes mellitusdyslipidemiafenofibratefibric acidshypertriglyceridemia |
| spellingShingle | Chaicharn Deerochanawong Sin Gon Kim Yu-Cheng Chang Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review Diabetes & Metabolism Journal asian people diabetes mellitus dyslipidemia fenofibrate fibric acids hypertriglyceridemia |
| title | Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review |
| title_full | Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review |
| title_fullStr | Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review |
| title_full_unstemmed | Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review |
| title_short | Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review |
| title_sort | role of fenofibrate use in dyslipidemia and related comorbidities in the asian population a narrative review |
| topic | asian people diabetes mellitus dyslipidemia fenofibrate fibric acids hypertriglyceridemia |
| url | http://e-dmj.org/upload/pdf/dmj-2023-0168.pdf |
| work_keys_str_mv | AT chaicharndeerochanawong roleoffenofibrateuseindyslipidemiaandrelatedcomorbiditiesintheasianpopulationanarrativereview AT singonkim roleoffenofibrateuseindyslipidemiaandrelatedcomorbiditiesintheasianpopulationanarrativereview AT yuchengchang roleoffenofibrateuseindyslipidemiaandrelatedcomorbiditiesintheasianpopulationanarrativereview |